: Despite being the first positive phase 3 trial in the adjuvant setting for early-stage hepatocellular carcinoma, the IMbrave050 study raises a number of questions regarding patient selection, endpoint robustness, and the balance between efficacy and acceptable toxicity.1.
The long and winding road: Adjuvant therapy for early-stage hepatocellular carcinoma
Rimassa, Lorenza
2024-01-01
Abstract
: Despite being the first positive phase 3 trial in the adjuvant setting for early-stage hepatocellular carcinoma, the IMbrave050 study raises a number of questions regarding patient selection, endpoint robustness, and the balance between efficacy and acceptable toxicity.1.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
D'Alessio_Adjuvant_HCC_Med_01.2024.pdf
non disponibili
Tipologia:
Versione Editoriale (PDF)
Licenza:
Copyright dell'editore
Dimensione
1.81 MB
Formato
Adobe PDF
|
1.81 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
